KIMYRSA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Kimyrsa, and what generic alternatives are available?
Kimyrsa is a drug marketed by Melinta Therap and is included in one NDA. There are three patents protecting this drug.
This drug has thirty-nine patent family members in seventeen countries.
The generic ingredient in KIMYRSA is oritavancin diphosphate. One supplier is listed for this compound. Additional details are available on the oritavancin diphosphate profile page.
DrugPatentWatch® Generic Entry Outlook for Kimyrsa
Kimyrsa was eligible for patent challenges on August 6, 2018.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for KIMYRSA?
- What are the global sales for KIMYRSA?
- What is Average Wholesale Price for KIMYRSA?
Summary for KIMYRSA
International Patents: | 39 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 27 |
Clinical Trials: | 2 |
Patent Applications: | 25 |
Drug Prices: | Drug price information for KIMYRSA |
What excipients (inactive ingredients) are in KIMYRSA? | KIMYRSA excipients list |
DailyMed Link: | KIMYRSA at DailyMed |
US Patents and Regulatory Information for KIMYRSA
KIMYRSA is protected by three US patents and three FDA Regulatory Exclusivities.
Patents protecting KIMYRSA
Methods of treatment using single doses of oritavancin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS WITH A SINGLE DOSE OF 1200MG ORITAVANCIN OR ITS SINGLE DOSE EQUIVALENT
High purity oritavancin and method of producing same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods of treating bacterial infections using oritavancin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS WITH A SINGLE DOSE OF 1200MG ORITAVANCIN OR ITS SINGLE DOSE EQUIVALENT
FDA Regulatory Exclusivity protecting KIMYRSA
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for KIMYRSA
See the table below for patents covering KIMYRSA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2570401 | ⤷ Sign Up | |
Hungary | S1600039 | ⤷ Sign Up | |
Eurasian Patent Organization | 201700019 | ВЫСОКОЧИСТЫЙ ОРИТАВАНЦИН И СПОСОБ ЕГО ПОЛУЧЕНИЯ | ⤷ Sign Up |
Japan | 2017521443 | 高純度のオリタバンシン及びその製造方法 | ⤷ Sign Up |
New Zealand | 591525 | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | ⤷ Sign Up |
New Zealand | 728401 | High purity oritavancin and method of producing same | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for KIMYRSA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2337575 | 132016000101430 | Italy | ⤷ Sign Up | PRODUCT NAME: ORITAVANCINA E I SUOI SALI DI ADDIZIONE FARMACEUTICAMENTE ACCETTABILI, IN PARTICOLARE IL DIFOSFATO(ORBACTIV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/989, 20150323 |
2337575 | 2016019 | Norway | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN OG FARMASOEYTISK; REG. NO/DATE: EU/1/15/989 20150415 |
2337575 | CA 2016 00044 | Denmark | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN OG/ELLER FARMACEUTISKE SALTE HERAF, HERUNDER DIFOSFATSALTE; REG. NO/DATE: EU/1/15/989 20150323 |
2337575 | 2016/040 | Ireland | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN AND PHARMACEUTICAL SALTS THEREOF, E.G DIPHOSPHATE SALTS; REGISTRATION NO/DATE: EU/1/15/989 20150319 |
2337575 | 16C0039 | France | ⤷ Sign Up | PRODUCT NAME: ORITAVANCINE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES,TELS QUE LES SELS DIPHOSPHATES; REGISTRATION NO/DATE: EU/1/15/989 20150323 |
2337575 | 41/2016 | Austria | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN UND DESSEN PHARMAZEUTISCHE SALZE; REGISTRATION NO/DATE: EU/1/15/989 (MITTEILUNG) 20150323 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |